Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2023 08:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in Virtual Fireside Chat On Computational Biology in Drug Discovery with Key Opinion Leaders

BETHESDA, Md., March 22, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
March 21, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

BETHESDA, Md., March 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company transforming drug discovery with its proprietary computational discovery platform...
March 09, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
February 27, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents New Preclinical Data from its Gaucher Disease Program at the 19th Annual WORLDSymposium

BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
February 02, 2023 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in Upcoming Scientific and Medical Conferences

BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
January 12, 2023 16:05 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
November 10, 2022 16:02 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder...
September 26, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons

Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek...
September 20, 2022 07:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer

BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary...
September 19, 2022 08:00 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson’s Disease...